Jeito Capital portfolio company Advesya emerges from stealth mode with the potential to become a leader in the treatment of hematological malignancies and other tumor treatments

Paris, France, 3 January 2024 – Jeito Capital (“Jeito”), a global leading independent private equity fund dedicated to biopharma, is pleased to announce the un-stealthing [1] of its portfolio company Advesya, a pioneering biopharma company for difficult-to-treat cancers.

The creation of the company was based on decades of research carried out by experienced scientists from the French Blood Institute (EFS) who decided to spin off the activity in 2021.
On the basis of their work, Jeito invested €23 million in January 2022 to get Advesya off the ground and to create a real market opportunity within the cancer therapy sector, starting with aiding refractory Acute Myeloid Leukemia patients, followed by other hematological malignancies.

The quality of the research and Jeito’s vision rapidly attracted an outstanding team from large Pharma players notably from Novartis, Celgene, AstraZeneca, each with excellent track records and years of expertise in the clinical development of innovative cancer treatments.

Ksenija Pavletic, Chief Commercial Officer at Jeito Capital, promoted to Partner Investor (see press release) with strong commercial and deep operational expertise, acted as CEO of the company since Jeito’s first investment.
In Besançon (France), she worked alongside the research team to develop a differentiated and unique target pathway technology to address the medical needs in patients with refractory myeloid cancers. The pathway technology has a potential for unprecedent efficacy and in some cases for a cure in hard-to-treat hematological cancers.

Jeito Capital will leverage Advesya’s breakthrough technology to grow and accelerate the company’s build-up strategy supporting it to become a leader in the treatment of hematological malignancies and other tumor treatments.

Rafaèle Tordjman, MD, PhD, Founder and CEO of Jeito Capital, said: “We are pleased to work with such a talented team whose leading technology has the potential to offer a major benefit to patients with high unmet needs.  I would like to pay tribute to the whole Advesya Team and to Ksenija who has been instrumental in the build-up strategy and growth of Advesya, on its path to become global market leader.”

[1] Most biotech or biopharma startups go through periods when they are hidden to the outside world, also known as “stealth mode,” a time of closed, private operations, when the company turns inward as it works to achieve its next phase of growth or research. When the company comes out of stealth mode it is ‘un-stealthing’

About Jeito Capital

Jeito Capital is a global leading Private Equity company with a patient benefit driven approach that finances and accelerates the development and growth of ground-breaking medical innovation. Jeito empowers and supports managers through its expert, integrated, multi-talented team and through the investment of significant capital to ensure the growth of companies, building market leaders in their respective therapeutic areas with accelerated patients’ access globally, especially in Europe and the United States. Jeito Capital has €534 million under management and a rapidly growing portfolio of investments. Jeito Capital is based in Paris with a presence in Europe and the United States.

For more information, please visit or follow us on Twitter or LinkedIn.

For further information please contact:

Jeito Capital
Rafaèle Tordjman
Jessica Fadel, EA
Tel: +33 6 33 44 25 47

H/Advisors Maitland
David Stürken
Tel: +44 (0) 799 059 5913